...Novus Therapeutics Inc. (NASDAQ:NVUS) and Otic Pharma Ltd. as well as the CBO role at Avanir Pharmaceuticals Inc....

...neuromuscular junctions. For further support, Hayden pointed to the studies of Nuedexta dextromethorphan hydrobromide from Avanir Pharmaceuticals Inc....
...a statistically significant effect on reducing pseudobulbar effect in patients with ALS and multiple sclerosis. Avanir...

...Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint...
...used in 15-AVP-786-302 (see "Avanir's AVP-786 Meets in Phase III for Alzheimer's Agitation" ). The Avanir Pharmaceuticals Inc....
...II testing for schizophrenia, intermittent explosive disorder and neurobehavioral dis-inhibition associated with traumatic brain injury. Avanir...

...Score from baseline to week 12 vs. placebo. However, a second dose missed the endpoint. Avanir Pharmaceuticals Inc....
...by a priori response criteria and re-randomized to receive either dose of AVP-786 or placebo. Avanir...
...weighted from both stages of the treatment periods was used to analyze the primary endpoint. Avanir...

...Development and Commercialization Inc. affiliate of Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan), and CMO of Avanir Pharmaceuticals Inc....

...OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate...
...migraine drug Onzetra Xsail in the U.S., Canada and Mexico (see "Avanir, OptiNose deal" ). Avanir...
...Japan Business: Drug delivery, Neurology Shannon Lehnbeuter Onzetra Xsail, sumatriptan nasal powder (avp-825, Intranasal sumatriptan powder, OptiNose sumatriptan) Avanir Pharmaceuticals Inc. OptiNose...

...of strategy and transformation, global R&D. CEO Palekar is the former CEO of neurology company Avanir Pharmaceuticals Inc....

...of strategy and transformation, global R&D. CEO Palekar is the former CEO of neurology company Avanir Pharmaceuticals Inc....

...acquisitions by Otsuka of U.S. companies include ADHD company Neurovance Inc. in 2017, CNS company Avanir Pharmaceuticals Inc....

...acquisitions by Otsuka of U.S. companies include ADHD company Neurovance Inc. in 2017, CNS company Avanir Pharmaceuticals Inc....